LV12493B - Plazmas olbaltumvielas saturoša farmaceitiska kompozīcija - Google Patents
Plazmas olbaltumvielas saturoša farmaceitiska kompozīcija Download PDFInfo
- Publication number
- LV12493B LV12493B LVP-00-38A LV000038A LV12493B LV 12493 B LV12493 B LV 12493B LV 000038 A LV000038 A LV 000038A LV 12493 B LV12493 B LV 12493B
- Authority
- LV
- Latvia
- Prior art keywords
- water
- product
- serum albumin
- protein fraction
- solution
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 47
- 102000004506 Blood Proteins Human genes 0.000 title claims abstract description 19
- 108010017384 Blood Proteins Proteins 0.000 title claims abstract description 19
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 61
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 61
- 239000013543 active substance Substances 0.000 claims abstract description 58
- 108010058237 plasma protein fraction Proteins 0.000 claims abstract description 53
- 229940081857 plasma protein fraction Drugs 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 52
- 239000007787 solid Substances 0.000 claims abstract description 50
- 230000008569 process Effects 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 137
- 239000000047 product Substances 0.000 claims description 82
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 67
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 66
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 66
- 229930012538 Paclitaxel Natural products 0.000 claims description 63
- 229960001592 paclitaxel Drugs 0.000 claims description 63
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 53
- 239000004480 active ingredient Substances 0.000 claims description 40
- 102000014150 Interferons Human genes 0.000 claims description 36
- 108010050904 Interferons Proteins 0.000 claims description 36
- 229940079322 interferon Drugs 0.000 claims description 35
- 238000009472 formulation Methods 0.000 claims description 34
- 102000003886 Glycoproteins Human genes 0.000 claims description 33
- 108090000288 Glycoproteins Proteins 0.000 claims description 33
- 102000015696 Interleukins Human genes 0.000 claims description 33
- 108010063738 Interleukins Proteins 0.000 claims description 33
- 239000000126 substance Substances 0.000 claims description 33
- 108060003951 Immunoglobulin Proteins 0.000 claims description 31
- 102000018358 immunoglobulin Human genes 0.000 claims description 31
- 102000007562 Serum Albumin Human genes 0.000 claims description 30
- 108010071390 Serum Albumin Proteins 0.000 claims description 30
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 28
- 229930105110 Cyclosporin A Natural products 0.000 claims description 28
- 108010036949 Cyclosporine Proteins 0.000 claims description 27
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims description 27
- 229960004134 propofol Drugs 0.000 claims description 27
- 108010074605 gamma-Globulins Proteins 0.000 claims description 26
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 25
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 23
- 229960003942 amphotericin b Drugs 0.000 claims description 23
- 102000009027 Albumins Human genes 0.000 claims description 22
- 108010088751 Albumins Proteins 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 21
- -1 taxonide Substances 0.000 claims description 21
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 20
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 20
- 229940127093 camptothecin Drugs 0.000 claims description 20
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 20
- 239000003960 organic solvent Substances 0.000 claims description 20
- 229960000623 carbamazepine Drugs 0.000 claims description 18
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 18
- 239000003381 stabilizer Substances 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 16
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 16
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 239000000654 additive Substances 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 13
- 239000012141 concentrate Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 12
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 11
- 229960002509 miconazole Drugs 0.000 claims description 11
- 230000004845 protein aggregation Effects 0.000 claims description 11
- 238000000108 ultra-filtration Methods 0.000 claims description 11
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 10
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 10
- 230000000996 additive effect Effects 0.000 claims description 10
- 229960002170 azathioprine Drugs 0.000 claims description 10
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 10
- 229960001265 ciclosporin Drugs 0.000 claims description 10
- 229960003627 gemfibrozil Drugs 0.000 claims description 10
- 229960000311 ritonavir Drugs 0.000 claims description 10
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 8
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 8
- 229960003387 progesterone Drugs 0.000 claims description 8
- 239000000186 progesterone Substances 0.000 claims description 8
- 229960001967 tacrolimus Drugs 0.000 claims description 8
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 8
- 229960001603 tamoxifen Drugs 0.000 claims description 8
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 7
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 claims description 7
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 claims description 7
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 claims description 7
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 7
- 239000003146 anticoagulant agent Substances 0.000 claims description 7
- 239000001961 anticonvulsive agent Substances 0.000 claims description 7
- 229960001671 azapropazone Drugs 0.000 claims description 7
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 claims description 7
- 229960002729 bromazepam Drugs 0.000 claims description 7
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 7
- 229960003120 clonazepam Drugs 0.000 claims description 7
- 229960003529 diazepam Drugs 0.000 claims description 7
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 7
- 229960001912 dicoumarol Drugs 0.000 claims description 7
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 claims description 7
- HIZKPJUTKKJDGA-UHFFFAOYSA-N dicumarol Natural products O=C1OC2=CC=CC=C2C(=O)C1CC1C(=O)C2=CC=CC=C2OC1=O HIZKPJUTKKJDGA-UHFFFAOYSA-N 0.000 claims description 7
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 claims description 7
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 7
- 229960002768 dipyridamole Drugs 0.000 claims description 7
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 claims description 7
- 229960001066 disopyramide Drugs 0.000 claims description 7
- 229960002200 flunitrazepam Drugs 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 229960004125 ketoconazole Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229960000916 niflumic acid Drugs 0.000 claims description 7
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 7
- 229960004535 oxazepam Drugs 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 229960003329 sulfinpyrazone Drugs 0.000 claims description 7
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 claims description 6
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims description 6
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 6
- 229960002036 phenytoin Drugs 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 229960003604 testosterone Drugs 0.000 claims description 6
- 229960000604 valproic acid Drugs 0.000 claims description 6
- 229960005080 warfarin Drugs 0.000 claims description 6
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000000824 cytostatic agent Substances 0.000 claims description 5
- 230000001085 cytostatic effect Effects 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 4
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 claims description 4
- 230000000202 analgesic effect Effects 0.000 claims description 4
- 239000003098 androgen Substances 0.000 claims description 4
- 230000003556 anti-epileptic effect Effects 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 230000003177 cardiotonic effect Effects 0.000 claims description 4
- 239000003218 coronary vasodilator agent Substances 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 230000000147 hypnotic effect Effects 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 125000001931 aliphatic group Chemical class 0.000 claims description 3
- 230000001773 anti-convulsant effect Effects 0.000 claims description 3
- 229960003965 antiepileptics Drugs 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 239000003504 photosensitizing agent Substances 0.000 claims description 3
- 239000003270 steroid hormone Substances 0.000 claims description 3
- 229940123635 Lipid peroxidase inhibitor Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 239000012263 liquid product Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims 3
- 230000003449 preventive effect Effects 0.000 claims 3
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical class O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229960000648 digitoxin Drugs 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 150000003077 polyols Chemical class 0.000 claims 2
- 229940124272 protein stabilizer Drugs 0.000 claims 2
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical group CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 claims 2
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 claims 1
- 239000003326 hypnotic agent Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000006201 parenteral dosage form Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000006104 solid solution Substances 0.000 claims 1
- 229960004492 suprofen Drugs 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 abstract description 63
- 230000002776 aggregation Effects 0.000 abstract description 39
- 238000004220 aggregation Methods 0.000 abstract description 39
- 235000018102 proteins Nutrition 0.000 description 53
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 20
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 14
- 239000012465 retentate Substances 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000008389 polyethoxylated castor oil Substances 0.000 description 8
- 239000003643 water by type Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- RBKASMJPSJDQKY-RBFSKHHSSA-N tirilazad Chemical compound O=C([C@@H]1[C@@]2(C)CC=C3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)CN(CC1)CCN1C(N=1)=CC(N2CCCC2)=NC=1N1CCCC1 RBKASMJPSJDQKY-RBFSKHHSSA-N 0.000 description 6
- 229960005155 tirilazad Drugs 0.000 description 6
- FMHHVULEAZTJMA-UHFFFAOYSA-N trioxsalen Chemical compound CC1=CC(=O)OC2=C1C=C1C=C(C)OC1=C2C FMHHVULEAZTJMA-UHFFFAOYSA-N 0.000 description 6
- 229960000850 trioxysalen Drugs 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000013467 fragmentation Methods 0.000 description 5
- 238000006062 fragmentation reaction Methods 0.000 description 5
- 229960002695 phenobarbital Drugs 0.000 description 5
- MDKGKXOCJGEUJW-UHFFFAOYSA-N suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 description 5
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
- 230000003288 anthiarrhythmic effect Effects 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000003424 uricosuric effect Effects 0.000 description 3
- 229930183010 Amphotericin Natural products 0.000 description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DZTHIGRZJZPRDV-UHFFFAOYSA-N N-acetyltryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 description 2
- 229940123742 Peroxidase inhibitor Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229940009444 amphotericin Drugs 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 229960004884 fluconazole Drugs 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- 210000003918 fraction a Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 101100235626 Caenorhabditis elegans hlb-1 gene Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 108010030471 Histamine N-methyltransferase Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010039238 Rouleaux formation Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- DFFDSQBEGQFJJU-UHFFFAOYSA-N butyl hydrogen carbonate Chemical compound CCCCOC(O)=O DFFDSQBEGQFJJU-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000701 toxic element Toxicity 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (39)
- LV 12493 Izgudrojuma formula 1. Odenī šķīstošs produkts, kas nesatur organisko šķīdinātāju vai zāļu forma cietā vai šķidrā veidā, kā arī to īstie ūdens šķīdumi, kas nesatur organisko šķīdinātāju, galvenokārt parenterālai ievadīšanai, satur a) ārstnieciski aktīvu vielu ar mazu šķīdību ūdenī (<1 χίΟ"4 M/L) un ievērojamu afinitāti pret plazmas olbaltumvielām (tālāk saukta “aktīvā viela"), b) plazmas olbaltumvielu frakciju ar noteiktu agregātstāvokli, pie kam minētā aktīvā viela un minētā olbaltumvielu frakcija ir savstarpēji saistītas ar nekovalentām saitēm, kas neobligāti papildus satur c) vienu vai vairākas farmaceitiski pieņemamas un, galvenokārt parenterālai ievadīšanai piemērotas zāļu formas palīgvielas, tādas kā ūdens, stabilizators(i) un olbaltumvielu agregācijas novērsējs(i).
- 2. Ūdenī šķīstošs produkts vai zāļu forma medicīniskām vajadzībām pēc 1. punkta, kas satur cilvēka plazmas olbaltumvielu frakciju ar noteiktu agregātstāvokli.
- 3. Ūdenī šķīstošs produkts vai zāļu forma veterinārām vajadzībām pēc 1. punkta, kas satur dzīvnieka plazmas olbaltumvielu frakciju ar noteiktu agregātstāvokli.
- 4. Produkts vai zāļu forma pēc jebkura no iepriekšējiem punktiem, kas kā plazmas olbaltumvielu frakciju satur dabīgās plazmas sastāvdaļu, piemēram, seruma albumīnu vai rekombinanto seruma albumīnu.
- 5. Produkts vai zāļu forma pēc jebkura no iepriekšējiem punktiem, kas kā plazmas olbaltumvielu frakciju satur dabīgo imūnglobulīnu, glikoproteīnu, interferonu un/vai interleikīnu vai rekombinanto imūnglobulīnu, glikoproteīnu, interferonu un/vai interleikīnu.
- 6. Produkts vai zāļu forma pēc jebkura no iepriekšējiem punktiem, kas kā ūdenī nešķīstošo aktīvo vielu satur citostatiķi, piemēram, taksonoīdu, antibiotiķi, vitamīnu, pretiekaisuma vielu, analgētikas, antivirālu vielu, antikonvulsantu, imūndepresantu, antiepileptisku vielu, anksiofītiķi, hipnotiķi, pretsēnīšu vielu, antikoagulantu, lipīdu peroksidāzes inhibitoru, koronāro vazodilatoru, antiaritmisku vielu, kardiotoniķi, urīndzenošu vielu, prettrombu vielu, steroīdhormonu (progesteronu, androgēnu, testogēnu) un/vai fotosensitizējošu vielu.
- 7. Produkts vai zāļu forma pēc jebkura no iepriekšējiem punktiem, kas satur vismaz vienu no šādām aktīvām vielām: amfotericīns B, adriamicīna analogs, apzaons, azatioprins, bromazepams, kamptotecins, karbamazepins, klonazepams, ciklosporīns A, diazepams, dikumarols, digitoksīns, dipiridamols, dizopiramids, flunitrazepams, gemfobrozils, ketohlorins, ketokonazols, mikonazols, niflumskābe, oksazepams, fenobarbitals, fenitoins, progesterons, propofols, ritonavirs, sulfinpirazons, suprofens, takrolims, tamoksifens, taksonoids, testosterons, tirilazads, trioksaiens, valprojskābe, varfarins, un kurā aktīvās vielas un olbaltumvielas molārās attiecības ir robežās no 1:0,05 līdz 1:100, vēlams - no 1:0,1 līdz 1:50.
- 8. Produkts vai zāļu forma pēc jebkura no iepriekšējiem punktiem, kas satur taksonoīdu ar kopējo formulu (I)kurā: R1 ir t-butoksikarboksamīda grupa vai benzamīda grupa. R2 ir ūdeņraža atoms vai acilgrupa, vēlams acetilgrupa.
- 9. Produkts vai zāļu forma pēc jebkura no iepriekšējiem punktiem, kas kā taksonoīdu satur paklitakselu kopā ar cilvēka seruma albumīnu, imūnglobulīnu, glikoproteīnu, interferonu un/vai interleikīnu vai kādu citu dabīgas vai rekombinantas cilvēka plazmas olbaltumvielas frakciju molārā attiecībā robežās no 1:0,05 līdz 1:100, vēlams - no 1:0,1 līdz 1:50.
- 10. Produkts vai zāļu forma pēc jebkura no iepriekšējiem punktiem, kas satur azatioprinu un cilvēka seruma albumīnu, imūnglobulīnu, glikoproteīnu, interferonu un/vai interleikīnu vai kādu citu dabīgas vai rekombinantas cilvēka LV 12493 plazmas olbaltumvielas frakciju molārā attiecībā robežās no 1:0,05 līdz 1:100, vēlams - no 1:0,1 līdz 1:50.
- 11. Produkts vai zāļu forma pēc jebkura no 1. līdz 8. punktam, kas satur kamptotecinu un cilvēka seruma albumīnu, imūnglobulīnu, glikoproteīnu, interferonu un/vai interleikīnu vai kādu citu dabīgas vai rekombinantas cilvēka plazmas olbaltumvielas frakciju molārā attiecībā robežās no 1:0,05 līdz 1:100, vēlams - no 1:0,1 līdz 1:50.
- 12. Produkts vai zāļu forma pēc jebkura no 1. līdz 8. punktam, kas satur gemfibrozilu un cilvēka seruma albumīnu, imūnglobulīnu, glikoproteīnu, interferonu un/vai interleikīnu vai kādu citu dabīgas vai rekombinantas cilvēka plazmas olbaltumvielas frakciju molārā attiecībā robežās no 1:0,05 līdz 1:100, vēlams - no 1:0,1 līdz 1:50.
- 13. Produkts vai zāļu forma pēc jebkura no 1. līdz 8. punktam, kas satur mikonazolu un cilvēka seruma albumīnu, imūnglobulīnu, glikoproteīnu, interferonu un/vai interleikīnu vai kādu citu dabīgas vai rekombinantas cilvēka plazmas olbaltumvielas frakciju molārā attiecībā robežās no 1:0,05 līdz 1:100, vēlams - no 1:0,1 līdz 1:50.
- 14. Produkts vai zāļu forma pēc jebkura no 1. līdz 8. punktam, kas satur propofolu un cilvēka seruma albumīnu, imūnglobulīnu, glikoproteīnu, interferonu un/vai interleikīnu vai kādu citu dabīgas vai rekombinantas cilvēka plazmas olbaltumvielas frakciju molārā attiecībā robežās no 1:0,05 līdz 1:100, vēlams - no 1:0,1 līdz 1:50.
- 15. Produkts vai zāļu forma pēc jebkura no 1. līdz 8. punktam, kas satur tamoksifenu un cilvēka seruma albumīnu, imūnglobulīnu, glikoproteīnu, interferonu un/vai Interleikīnu vai kādu citu dabīgas vai rekombinantas cilvēka plazmas olbaltumvielas frakciju molārā attiecībā robežās no 1:0,05 līdz 1:100, vēlams - no 1:0,1 līdz 1:50.
- 16. Produkts vai zāļu forma pēc jebkura no 1. līdz 8. punktam, kas satur ritonaviru un cilvēka seruma albumīnu, imūnglobulīnu, glikoproteīnu, interferonu un/vai interleikīnu vai kādu citu dabīgas vai rekombinantas cilvēka plazmas olbaltumvielas frakciju molārā attiecībā robežās no 1:0,05 līdz 1:100, vēlams - no 1:0,1 līdz 1:50.
- 17. Produkts vai zāļu forma pēc jebkura no 1. līdz 8. punktam, kas satur takrolimu un cilvēka seruma albumīnu, imūnglobulīnu, glikoproteīnu, interferonu un/vai interleikīnu vai kādu citu dabīgas vai rekombinantas cilvēka plazmas olbaltumvielas frakciju molārā attiecībā robežās no 1:0,05 līdz 1:100, vēlams - no 1:0,1 līdz 1:50.
- 18. Produkts vai zāļu forma pēc jebkura no 1. līdz 8. punktam, kas satur tirilazadu un cilvēka seruma albumīnu, imūnglobulīnu, glikoproteīnu, interferonu un/vai interleikīnu vai kādu citu dabīgas vai rekombinantas cilvēka plazmas olbaltumvielas frakciju molārā attiecībā robežās no 1:0,05 līdz 1:100, vēlams - no 1:0,1 līdz 1:50.
- 19. Produkts vai zāļu forma pēc jebkura no 1. līdz 8. punktam, kas satur trioksalenu un cilvēka seruma albumīnu, imūnglobulīnu, glikoproteīnu, interferonu un/vai interleikīnu vai kādu citu dabīgas vai rekombinantas cilvēka plazmas olbaltumvielas frakciju molārā attiecībā robežās no 1:0,05 līdz 1:100, vēlams - no 1:0,1 fīdz 1:50.
- 20. Zāļu forma pēc jebkura no iepriekšējiem punktiem, kas ir cietā vai ūdens šķīduma veidā.
- 21. Zāļu forma pēc jebkura no iepriekšējiem punktiem, kas kā piedevu satur šķīduma un/vai olbaltumvielas stabilizatoru.
- 22. Zāļu forma pēc 21. punkta, kas kā šķīduma un/vai olbaltumvielas stabilizatoru satur vielu no rindas: nātrija hlorīds, bufers, spirts, piemēram, glicerīns, un/vai ūdenī šķīstošu cukura atvasinājumu, vēlams mannitolu, sorbitolu vai dulcitolu.
- 23. Paņēmiens ūdenī šķīstoša produkta vai zāļu formas cietā vai šķīuma veidā pēc jebkura no iepriekšējiem punktiem iegūšanai vai produkta pēc jebkura no 29. līdz 36. punktam iegūšanai vai to īstu, organisko šķīdinātāju nesaturošu, ūdens šķīdumu iegūšanai, kas atšķiras ar to, ka īstu ūdens šķīdumu pagatavo a) izšķīdinot ārstnieciski aktīvu vielu ar mazu šķīdību ūdenī (c^lO"4 M/L) un ievērojamu afinitāti pret plazmas olbaltumvielām (tālāk saukta “aktīvā viela”) farmaceitiski pieņemamā organiskā šķīdinātājā, kas jaucas ar ūdeni, b) sajaucot minēto šķīdinātāju ar plazmas olbaltumvielu frakcijas, kas atrodas noteiktā agregātstāvoklī, ūdens šķīdumu un c) neobligātu farmaceitiski pieņemamu ūdenī šķīstošu palīgvielu, piemēram, olbaltumvielas agregācijas novērsēju un/vai stabilizētāju, pie kam iegūst īstu šķīdumu, kas satur minēto aktīvo vielu un minēto olbaltumvielas frakciju, kas savstarpēji saistītas ar nekovalentām saitēm; d) aizvācot organisko šķīdinātāju un neobligāti arī ūdeni, vēlams šķīduma vai tā koncentrāta ultrafiltrācijas, dialīzes, diafiltrācijas un/vai liofilizācijas palīdzību vai minēto paņēmienu kombināciju, pie kam tiek iegūts homogēns, ūdenī šķīstošs šķidrums vai ciets farmaceitiskais produkts, kas satur aktīvo vielu, kas ir saistīta ar plazmas olbaltumvielu frakciju; e) neobligāti šķīdinot iegūto produktu ūdenī vai atšķaidot šķidro produktu ar ūdeni, tā iegūstot dzidru, īstu ūdens šķīdumu, kas nesatur nevienu organisko šķīdinātāju un ir piemērots ievadīšanai terapeitiskos nolūkos, un f) neobligāti sagatavojot minēto produktu parenterālā zāļu formā tiešai izmantošanai.
- 24. Paņēmiens ūdenī šķīstoša produkta vai zāļu formas cietā vai šķīuma veidā pēc jebkura no 1. līdz 22. punktam iegūšanai vai produkta pēc LV 12493 jebkura no 29. līdz 36. punktam iegūšanai vai to īstu, organisko šķīdinātāju nesaturošu, ūdens šķīdumu iegūšanai, kas atšķiras ar to, ka īstu ūdens šķīdumu pagatavo a) izšķīdinot ārstnieciski aktīvu vielu farmaceitiski pieņemamā organiskā šķīdinātājā, kas jaucas ar ūdeni, b) sajaucot minēto šķīdinātāju ar plazmas olbaltumvielu frakcijas, kas atrodas noteiktā agregātstāvoklī, ūdens šķīdumu, c) pie kam minētais šķīdums neobligāti satur arī farmaceitiski pieņemamu ūdenī šķīstošu palīgvielu, piemēram, olbaltumvielas agregācijas novērsēju un/vai stabilizētāju, pie kam iegūst īstu šķīdumu, kas satur minēto aktīvo vielu un minēto olbaltumvielas frakciju, kas savstarpēji saistītas ar nekovaientām saitēm; d) aizvācot organisko šķīdinātāju un liofilizējot šķīdumu vai tā koncentrātu.
- 25. Paņēmiens pēc 23. vai 24. punkta, kurā posms a) atšķiras ar to, ka aktīvās vielas šķīdināšanai tiek izmantots šķīdinātājs ar šādām īpašībām: a) maisījumā ar ūdeni tas spēj pilnībā izšķīdināt aktīvo vielu un b) maisījumā, kur ūdens saturs ir <50%, tas nedenaturalizē izmantoto olbaltumvielu. fif SĶ
- 26. Paņēmiens pēc 25. punkta, kas atšķiras ar to, ka par šķīdinātāju izmanto vielu no rindas: alifātiskais C2^alkanols vai poliols, 70-100% etanols, dimetilformamīds, metilformamīds.
- 27. Paņēmiens pēc jebkura no 23. līdz 26. punktam, kas atšķiras ar to, ļ; ka par olbaltumvielas agregācijas novērsēju vai stabilizatoru un/vai šķīdumu ^ stabilizējošo palīgvielu izmanto vielu no rindas: ūdens, nātrija hlorīds, bufers, poliols, piemēram, glicerīns un/vai ūdenī šķīstošs cukura atvasinājums, vēlams mannltols, sorbitols un/vai dulcitols.
- 28. Paņēmiens pēc jebkura no 23. līdz 27. punktam, kurā punkts a) atšķiras ar to, ka tiek izmantots paklitaksels un dabīgās plazmas olbaltumviela, piemēram, seruma albumīns, imūnglobulīns, glikoproteīns, interferons un/vai interleikīns vai rekombinantais seruma albumīns, imūnglobulīns, glikoproteīns, interferons un/vai interleikīns.
- 29. Homogēns, ciets, ūdenī šķīstošs produkts, kas paredzēts pielietojumam ārstniecībā un kas sastāv vismaz no vienas aktīvās vielas ar mazu šķīdību ūdenī (<1 ^10-4 M/L), kas ņemts no rindas: amfotericīns B, adriamicīna analogs, apzaons, azatioprins, bromazepams, kamptotecins, karbamazepins, klonazepams, ciklosporīns A, diazepams, dikumarols, digitoksīns, dipiridamols, dizopiramids, flunitrazepams, gemfobrozils, ketohlorins, ketokonazols, mikonazols, niflumskābe, oksazepams, fenobarbitals, fenitoins, progesterons, propofols, ritonavirs, sulfinpirazons, suprofens, takrolims, tamoksifens, taksonoids, testosterons, tirilazads, trioksalens, valprojskābe un varfarins, vismaz vienas olbaltumvielas, kas ņemta no rindas: cilvēka seruma albumīns, imūnglobulīns, glikoproteīns, interferons un interleikīns vai cita dabīgā vai rekombinantā cilvēka plazmas seruma olbaltumvielas frakcija, pie kam minētā aktīvā viela un minētā olbaltumvielas frakcija ir savstarpēji saistītas ar nekovalentām saitēm, pie tam minētās aktīvās vielas un minētās olbaltumvielas frakcijas molārās attiecības ir robežās no 1:0,05 līdz 1:100, vēlams no 1:0,1 līdz 1:50.
- 30. Homogēns, ciets, ūdenī šķīstošs produkts pēc 30. punkta, kas satur taksonoīdu ar kopējo formulu (I)kurā: R1 ir t-butoksikarboksamīda grupa vai benzamīda grupa, R2 ir ūdeņraža atoms vai acilgrupa, vēlams acetilgrupa, kopā ar plazmas olbaltumvielas frakciju.
- 31. Homogēns, ciets, ūdenī šķīstošs produkts pēc 29. punkta, kas satur paklitakselu un cilvēka seruma albumīnu, rekombinanto cilvēka plazmas albumīnu un/vai γ-globulīnu.
- 32. Homogēns, ciets, ūdenī šķīstošs produkts pēc 29. punkta, kas satur amfotericinu B un cilvēka seruma albumīnu, rekombinanto cilvēka plazmas albumīnu un/vai γ-globulīnu.
- 33. Homogēns, ciets, ūdenī šķīstošs produkts pēc 29. punkta, kas satur kamptotecinu un cilvēka seruma albumīnu, rekombinanto cilvēka plazmas albumīnu un/vai γ-globulīnu. 7 7 LV 12493
- 34. Homogēns, ciets, ūdenī šķīstošs produkts pēc 29. punkta, kas satur karbamazepinu un cilvēka seruma albumīnu, rekombinanto cilvēka plazmas albumīnu un/vai γ-globulīnu.
- 35. Homogēns, ciets, ūdenī šķīstošs produkts pēc 29. punkta, kas satur ciklosporinu A un cilvēka seruma albumīnu, rekombinanto cilvēka plazmas albumīnu un/vai γ-globulīnu.
- 36. Homogēns, ciets, ūdenī šķīstošs produkts pēc 29. punkta, kas satur propofolu un cilvēka seruma albumīnu, rekombinanto cilvēka plazmas albumīnu un/vai γ-globulīnu.
- 37. Vielas vai zāļu formas pēc jebkura no/ pagatavotas pēc jebkura no 1-36 punktam pielietojums ārstniecības preparāta ražošanai, kas paredzēts humāno vai veterināro pacientu ārstēšanai.
- 38. Pielietojums pēc 37. punkta parenterāli ievadāma ārstniecības preparāta ražošanai, izmantojot šādas vielas un, attiecīgi, devas (vēlamo devu robežas dotas attiecībā uz aktīvo vielu): paklitaksels/albumīns 70-280 mg/ārstēšanas kursam; propofols/albumīns 6-10 mg/kg/h; kamptotecins/albumīns; gemfibrozils/albumīns; ciklosporīns A/albumīns 3-5 mg/kg/dienā; amfotericins B/albumīns līdz 1,5 mg/kg/dienā, attiecīgi tādu pašu devu izmantojot rekombinanto olbaltumvielu gadījumā.
- 39. Kompozīcijas pēc jebkura no/ pagatavotas pēc jebkura no 1-28 punktam pielietojums parenterāli ievadāma ārstniecības preparāta iegūšanai.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9701554A HUP9701554D0 (en) | 1997-09-18 | 1997-09-18 | Pharmaceutical composition containing plazma proteins |
| PCT/HU1998/000086 WO1999013914A1 (en) | 1997-09-18 | 1998-09-17 | Pharmaceutical compositions containing plasma protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV12493A LV12493A (en) | 2000-06-20 |
| LV12493B true LV12493B (lv) | 2001-01-20 |
Family
ID=90014222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-00-38A LV12493B (lv) | 1997-09-18 | 2000-03-14 | Plazmas olbaltumvielas saturoša farmaceitiska kompozīcija |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US6743826B1 (lv) |
| EP (1) | EP0981375B1 (lv) |
| JP (1) | JP2001508806A (lv) |
| KR (1) | KR100587962B1 (lv) |
| CN (1) | CN1189216C (lv) |
| AR (1) | AR017120A1 (lv) |
| AT (1) | ATE230611T1 (lv) |
| AU (1) | AU734695B2 (lv) |
| BG (1) | BG64749B1 (lv) |
| BR (1) | BR9812469A (lv) |
| CA (1) | CA2269923C (lv) |
| CZ (1) | CZ301326B6 (lv) |
| DE (1) | DE69810612T2 (lv) |
| DK (1) | DK0981375T3 (lv) |
| EA (1) | EA004700B1 (lv) |
| ES (1) | ES2187062T3 (lv) |
| HR (1) | HRP980499A2 (lv) |
| HU (1) | HUP9701554D0 (lv) |
| IL (1) | IL135055A (lv) |
| LT (1) | LT4736B (lv) |
| LV (1) | LV12493B (lv) |
| NO (1) | NO325294B1 (lv) |
| NZ (1) | NZ503302A (lv) |
| PL (1) | PL193067B1 (lv) |
| PT (1) | PT981375E (lv) |
| RO (1) | RO118695B1 (lv) |
| RS (1) | RS50102B (lv) |
| SI (1) | SI20189B (lv) |
| SK (1) | SK284683B6 (lv) |
| TR (1) | TR200001545T2 (lv) |
| TW (1) | TWI222365B (lv) |
| WO (1) | WO1999013914A1 (lv) |
| ZA (1) | ZA988585B (lv) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US8137684B2 (en) * | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| HUP9701554D0 (en) * | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
| WO2000047187A1 (en) * | 1999-02-11 | 2000-08-17 | Kinetana Inc. | Serum albumin-based parenteral formulations of polyene macrolides |
| IL148234A0 (en) | 1999-09-16 | 2002-09-12 | Novo Nordisk As | Composition for ivf |
| AU2001253336A1 (en) * | 2000-04-10 | 2001-10-23 | Teva Pharmaceutical Industries Ltd. | Method 0f administration of paclitaxel-plasma protein formulation |
| IL152180A0 (en) * | 2000-04-10 | 2003-05-29 | Teva Pharma | Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents |
| CA2445763A1 (en) * | 2001-05-01 | 2002-11-07 | Angiotech Pharmaceuticals Inc. | Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions |
| EP2261250B1 (en) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin fusion proteins |
| GR1004274B (el) | 2002-07-16 | 2003-06-23 | Medexis ���� | Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες |
| CA2492297A1 (en) | 2002-07-16 | 2004-01-22 | Medexis S.A. | Steroid conjugates, preparation thereof and the use thereof |
| AU2003262025A1 (en) * | 2002-09-12 | 2004-04-30 | Nihon Medi-Physics Co., Ltd. | Preparation for controlling binging of drug to plasma protein |
| KR20200083657A (ko) | 2002-12-09 | 2020-07-08 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| WO2004101620A2 (en) * | 2003-05-01 | 2004-11-25 | Compound Therapeutics, Inc. | Serum albumin scaffold-based proteins and uses thereof |
| US20040225022A1 (en) * | 2003-05-09 | 2004-11-11 | Desai Neil P. | Propofol formulation containing reduced oil and surfactants |
| US7659310B2 (en) | 2004-04-27 | 2010-02-09 | Formatech, Inc. | Methods of enhancing solubility of agents |
| US7345093B2 (en) | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
| US20050277584A1 (en) * | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| EP1807146A4 (en) * | 2004-09-29 | 2013-07-03 | Tel Hashomer Medical Res Infrastructure & Services Ltd | COMPOSITION FOR IMPROVING THE EFFICACY OF DRUG DELIVERY |
| US20060198891A1 (en) * | 2004-11-29 | 2006-09-07 | Francois Ravenelle | Solid formulations of liquid biologically active agents |
| US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| EP2066309B1 (en) | 2007-04-04 | 2012-08-29 | Sigmoid Pharma Limited | An oral pharmaceutical composition |
| EP2061587A1 (en) | 2007-04-26 | 2009-05-27 | Sigmoid Pharma Limited | Manufacture of multiple minicapsules |
| WO2009116557A1 (ja) * | 2008-03-21 | 2009-09-24 | 富士フイルム株式会社 | 薬剤含有組成物 |
| CN101658516B (zh) * | 2008-08-26 | 2011-10-05 | 齐鲁制药有限公司 | 紫杉醇类药物组合物及其制备方法 |
| CA2762179A1 (en) | 2009-05-18 | 2010-11-25 | Sigmoid Pharma Limited | Composition comprising oil drops |
| CN107582526A (zh) | 2009-08-12 | 2018-01-16 | 希格默伊德药业有限公司 | 包含聚合物基质和油相的免疫调节组合物 |
| US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
| EP2480208A1 (en) | 2009-09-23 | 2012-08-01 | Indu Javeri | Methods for the preparation of liposomes |
| US9629920B2 (en) | 2009-12-18 | 2017-04-25 | Exodos Life Sciences Limited Partnership | Methods and compositions for stable liquid drug formulations |
| WO2011097149A2 (en) * | 2010-02-03 | 2011-08-11 | Oncbiomune, L.L.C. | Taxane-and taxoid-protein compositions |
| AR093275A1 (es) | 2010-03-17 | 2015-05-27 | Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) | Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| AU2015232994B2 (en) | 2014-03-18 | 2020-05-28 | Izun Pharmaceuticals Corp. | Protein-bound cannabinoid compositions |
| AU2015341695B2 (en) | 2014-11-07 | 2021-07-08 | Sublimity Therapeutics Limited | Compositions comprising cyclosporin |
| AR100034A1 (es) | 2015-01-30 | 2016-09-07 | Consejo Nac De Investig Científicas Y Técnicas (Conicet) | Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas |
| EP3294900B1 (en) * | 2015-05-08 | 2021-09-22 | Spectral Platforms, Inc. | Use of albumin-based non-covalent complexes for the detection of micro-organisms |
| CN112807299B (zh) | 2015-05-15 | 2022-06-24 | 珠海贝海生物技术有限公司 | 包含多西他赛和人血清白蛋白的固体组合物及其制备方法和应用 |
| EP3310338A4 (en) * | 2015-06-18 | 2018-12-26 | Matinas BioPharma Nanotechnologies, Inc. | Compositions and methods for treating inflammatory disease or conditions |
| WO2017083397A1 (en) * | 2015-11-09 | 2017-05-18 | Cayo Max A | Cardiac glycosides for the treatment of hypercholesterolemia |
| WO2018027029A1 (en) * | 2016-08-03 | 2018-02-08 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of fosaprepitant and aprepitant |
| CN110062622B (zh) | 2016-10-27 | 2022-10-14 | 珠海贝海生物技术有限公司 | 多西他赛和人血清白蛋白的中性pH组合物 |
| RU2019131436A (ru) | 2017-03-09 | 2021-04-10 | Изун Фармасьютикалс Корп. | Стабилизированные композиции связанных с белком каннабиоидов |
| US11105747B2 (en) | 2017-03-20 | 2021-08-31 | Spectral Platforms, Inc. | Spectroscopic methods to detect and characterize microorganisms |
| MX2020000265A (es) | 2017-07-07 | 2020-07-22 | Epicentrx Inc | Composiciones para la administración parenteral de agentes terapéuticos. |
| AU2019232153B2 (en) * | 2018-03-09 | 2023-07-13 | Panoptes Pharma Ges.M.B.H. | Ophthalmic formulation |
| EP3811982A1 (en) * | 2019-10-25 | 2021-04-28 | Université de Strasbourg | Protein-based biomaterial with viscoelastic behaviour, process for obtaining it and uses thereof |
| CN111529506B (zh) * | 2020-05-18 | 2021-09-03 | 同济大学 | 一种两性霉素b白蛋白纳米制剂及其制备方法和应用 |
| US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
| KR102435211B1 (ko) * | 2021-06-29 | 2022-08-23 | (주)진셀바이오텍 | 알부민을 고효율로 생산하는 식물 세포주 및 이의 용도 |
| CN114544926A (zh) * | 2021-12-02 | 2022-05-27 | 浙江鑫科医疗科技有限公司 | 一种血清蛋白稳定剂 |
| CN115236216B (zh) * | 2022-06-07 | 2024-03-01 | 合肥和合医疗科技有限公司 | 高效液相色谱串联质谱检测全血中免疫抑制剂的试剂盒，其制备方法和检测方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4833013A (lv) * | 1971-08-30 | 1973-05-07 | ||
| DE2653534C2 (de) * | 1975-12-22 | 1986-08-28 | Baxter Travenol Laboratories, Inc., Deerfield, Ill. | Feste Antihämophilen-Faktor-Präparation und Verfahren zu ihrer Herstellung |
| JPS58216126A (ja) * | 1982-06-11 | 1983-12-15 | Ono Pharmaceut Co Ltd | 可容化製剤 |
| DE3702105A1 (de) * | 1987-01-24 | 1988-08-04 | Bayer Ag | Parenterale loesung |
| JPS63215640A (ja) * | 1987-03-04 | 1988-09-08 | Nippon Hai Potsukusu:Kk | 易吸収性抗炎症剤及びその製造方法 |
| EP0326618A1 (en) * | 1987-03-04 | 1989-08-09 | Nippon Hypox Laboratories Incorporated | Medicinal composition containing albumin as carrier and process for its preparation |
| CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| US5356927A (en) * | 1992-12-02 | 1994-10-18 | Thomas Jefferson University | Methods of treating plasmodium and babesia parasitic infections |
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| GB9510716D0 (en) * | 1995-05-26 | 1995-07-19 | Pharmacia Spa | Substituted camptothecin derivatives and process for their preparation |
| TR199600775A2 (tr) | 1996-09-27 | 1997-09-21 | Tureks Turunc Madencilik Ic Ve | Taslara eskitilmis görüntü kazandirilmasi icin bir yöntem. |
| US5776912A (en) * | 1996-12-20 | 1998-07-07 | Schering Corporation | Lipophilic oligosaccharide antibiotic compositions |
| HUP9701554D0 (en) * | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
| ITMI20001107A1 (it) * | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
-
1997
- 1997-09-18 HU HU9701554A patent/HUP9701554D0/hu unknown
-
1998
- 1998-09-10 HR HRP9701554A patent/HRP980499A2/hr not_active Application Discontinuation
- 1998-09-17 DK DK98946629T patent/DK0981375T3/da active
- 1998-09-17 TR TR2000/01545T patent/TR200001545T2/xx unknown
- 1998-09-17 PT PT98946629T patent/PT981375E/pt unknown
- 1998-09-17 RO ROA200000315A patent/RO118695B1/ro unknown
- 1998-09-17 SI SI9820067A patent/SI20189B/sl active Search and Examination
- 1998-09-17 EP EP98946629A patent/EP0981375B1/en not_active Expired - Lifetime
- 1998-09-17 SK SK329-2000A patent/SK284683B6/sk not_active IP Right Cessation
- 1998-09-17 AT AT98946629T patent/ATE230611T1/de active
- 1998-09-17 ES ES98946629T patent/ES2187062T3/es not_active Expired - Lifetime
- 1998-09-17 DE DE69810612T patent/DE69810612T2/de not_active Expired - Lifetime
- 1998-09-17 BR BR9812469-2A patent/BR9812469A/pt not_active Application Discontinuation
- 1998-09-17 IL IL13505598A patent/IL135055A/en not_active IP Right Cessation
- 1998-09-17 KR KR1020007002810A patent/KR100587962B1/ko not_active IP Right Cessation
- 1998-09-17 CA CA002269923A patent/CA2269923C/en not_active Expired - Lifetime
- 1998-09-17 EA EA200000331A patent/EA004700B1/ru not_active IP Right Cessation
- 1998-09-17 NZ NZ503302A patent/NZ503302A/en unknown
- 1998-09-17 CN CNB988092514A patent/CN1189216C/zh not_active Expired - Fee Related
- 1998-09-17 AU AU93623/98A patent/AU734695B2/en not_active Ceased
- 1998-09-17 JP JP51757699A patent/JP2001508806A/ja not_active Withdrawn
- 1998-09-17 PL PL339369A patent/PL193067B1/pl unknown
- 1998-09-17 WO PCT/HU1998/000086 patent/WO1999013914A1/en not_active Application Discontinuation
- 1998-09-17 CZ CZ20000952A patent/CZ301326B6/cs not_active IP Right Cessation
- 1998-09-17 RS YUP-166/00A patent/RS50102B/sr unknown
- 1998-09-18 ZA ZA9808585A patent/ZA988585B/xx unknown
- 1998-09-18 AR ARP980104659A patent/AR017120A1/es not_active Application Discontinuation
- 1998-09-18 TW TW087115619A patent/TWI222365B/zh not_active IP Right Cessation
-
1999
- 1999-04-27 US US09/299,562 patent/US6743826B1/en not_active Expired - Lifetime
-
2000
- 2000-03-14 LV LVP-00-38A patent/LV12493B/lv unknown
- 2000-03-16 NO NO20001371A patent/NO325294B1/no not_active IP Right Cessation
- 2000-03-16 BG BG104245A patent/BG64749B1/bg unknown
- 2000-03-17 LT LT2000018A patent/LT4736B/lt not_active IP Right Cessation
-
2003
- 2003-01-21 US US10/349,492 patent/US7119124B2/en not_active Expired - Lifetime
-
2004
- 2004-03-17 US US10/802,528 patent/US7501455B2/en not_active Expired - Fee Related
-
2006
- 2006-10-10 US US11/546,518 patent/US20070232536A1/en not_active Abandoned
-
2009
- 2009-02-09 US US12/322,997 patent/US8946167B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LV12493B (lv) | Plazmas olbaltumvielas saturoša farmaceitiska kompozīcija | |
| Zhao et al. | A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity | |
| JP2003534265A (ja) | 生物学的に活性な親水性化合物を非経口的に投与するための徐放性薬剤組成物 | |
| JP2001524990A (ja) | リポソームに封入されたタキサンの投与方法 | |
| US20120039983A1 (en) | Amphiphilic macromolecule-lipid complexes | |
| JPH09512261A (ja) | タキサン系の誘導体に基づく製薬組成物 | |
| CA3023227C (en) | Pharmaceutical composition containing macromolecular drug | |
| EP1701699A2 (en) | Pharmaceutical compositions | |
| KR20220045203A (ko) | 암 치료에 따른 화학요법-유도된 말초 신경병증 치료를 위한 palm | |
| HU223974B1 (hu) | Plazma protein tartalmú gyógyszerkészítmények és eljárás előállításukra | |
| MXPA00002561A (en) | Pharmaceutical compositions containing plasma protein | |
| WO2005017079A1 (en) | Process for the purification of non-ionic solvants for stabilized injectable pharmaceutical formulaitons |